The identification of the EML4-ALK fusion gene in nonsmall cell lung cancer (NSCLC) was reported in 2007 [62], and within 3 years ORR of 57% and median 6 months PFS of 72% in pretreated patients with NSCLC with the EML4-ALK translocation was reported [63]. This evidence concerns the gene ALK and lung cancer.